文献速递糖尿病肥胖与代谢综合征

Roux-en-Y胃旁路术后2型糖尿病缓解者的β细胞功能与质量对比

Beta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass.
PubMed 文献 · Diabetologia · 2026-01-20

该探索性概念验证研究用[68Ga]Ga-NODAGA-exendin-4 PET/CT量化β细胞质量,比较RYGB术后2型糖尿病缓解者(n=8)与未缓解者(n=9)的β细胞功能与质量。结果显示缓解者β细胞功能更高,但两组β细胞质量无差异,提示RYGB可能不增加β细胞质量。

要点

  • RYGB术后2型糖尿病缓解者β细胞功能显著优于未缓解者。
  • 两组β细胞质量无差异,且与β细胞功能或体重参数不相关。
  • 缓解者糖尿病病程较未缓解者更短。

核心结论

  • RYGB术后2型糖尿病缓解者β细胞功能优于未缓解者,但两组β细胞质量无差异。
  • 初步数据不支持RYGB对β细胞质量有刺激作用,非功能性β细胞复活可能是缓解机制之一。

研究设计与样本

  • 探索性概念验证研究,比较RYGB术后2型糖尿病缓解者(n=8)与未缓解者(n=9)。
  • 以[68Ga]Ga-NODAGA-exendin-4 PET/CT量化β细胞质量,注射剂量100 ± 5.6 MBq。
  • β细胞功能通过联合精氨酸刺激试验(ARGT)和OGTT的C肽AUC及C肽AUC与葡萄糖AUC比值确定。

主要发现

  • 缓解者糖尿病病程短于未缓解者。
  • ARGT中AUCC-peptide/fasting glucose缓解者为1.1 ± 0.41 vs 未缓解者0.32 ± 0.16 nmol × min/mmol,p=0.001。
  • OGTT中AUCC-peptide:AUCglucose缓解者为0.15 [0.11-0.24] vs 未缓解者0.032 [0.023-0.054],p=0.005。
  • β细胞质量两组分别为3.6 [3.4-5.4] vs 3.8 [1.9-4.5] kBq/MBq,p=0.87,且与β细胞功能或体重参数不相关。
  • HOMA2-%B在缓解组更优,RYGB术后显著改善,未缓解组无变化。

临床怎么用

  • RYGB术后2型糖尿病缓解可能与β细胞功能改善有关,而非β细胞质量增加。
  • 评估RYGB疗效时,β细胞功能指标(如ARGT、OGTT衍生指标、HOMA2-%B)可提供参考。

局限性

  • 探索性概念验证研究,样本量小(缓解组n=8,未缓解组n=9)。
  • β细胞质量测量方法及非功能性β细胞复活假说需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: In people with type 2 diabetes and obesity, Roux-en-Y gastric bypass (RYGB) can induce remission of diabetes. While RYGB has been reported to improve beta cell function in individuals with type 2 diabetes, it is unclear whether this is accompanied by changes in beta cell mass. In this explorative proof-of-concept study, we compared beta cell mass, measured by [68Ga]Ga-NODAGA-exendin-4 positron emission tomography/computed tomography (PET/CT) imaging, between individuals achieving remission of type 2 diabetes following RYGB and those not achieving remission. METHODS: Individuals with (n=8) and without (n=9) remission of type 2 diabetes up to 4 years after RYGB were injected with 100 ± 5.6 MBq of [68Ga]Ga-NODAGA-exendin-4 to quantify beta cell mass using PET/CT imaging. Beta cell function was determined by the AUC for C-peptide and the ratio between the AUC for C-peptide and AUC for glucose obtained from a combined arginine stimulation test (ARGT) and OGTT. Acquired variables are expressed as mean ± SD or median (IQR) based on normality. RESULTS: Individuals with remission of type 2 diabetes had a shorter diabetes duration than those without remission. After RYGB, beta cell function was higher in individuals with remission of type 2 diabetes than individuals without remission, based on both ARGTs (AUCC-peptide/fasting glucose 1.1 ± 0.41 vs 0.32 ± 0.16 nmol × min/mmol, p=0.001) and OGTTs (AUCC-peptide:AUCglucose 0.15 [0.11-0.24] vs 0.032 [0.023-0.054], p=0.005). In contrast, beta cell mass did not differ between individuals with or without remission of type 2 diabetes (3.6 [3.4-5.4] vs 3.8 [1.9-4.5] kBq/MBq, p=0.87) and did not correlate with beta cell function or body weight parameters. HOMA2-%B, also representing beta cell function, was better in the remission group and significantly improved in these individuals after RYGB, whereas it remained unchanged in non-remitters. CONCLUSIONS/INTERPRETATION: Individuals with remission of type 2 diabetes after RYGB have better beta cell function than those not achieving remission, but the groups did not differ with respect to beta cell mass. Our preliminary data argue against a stimulating effect of RYGB on beta cell mass, although revival of non-functional (so-called dormant) beta cells is a possible explanation for remission. TRIAL REGISTRATION: ClinicalTrials.gov NCT02542059.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Tokgöz S, Deden LN, Hofboer A, et al. Beta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass. Diabetologia. 2026. PMID: 41555052. doi:10.1007/s00125-025-06659-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。